Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Industry-HCP cooperation and future trends
What are the most critical aspects of ethical interactions between the industry and HCPs? What is the current framework of industry-HCP cooperation and what can we expect in the future? How is the role of HCPs and the industry evolving?
“I think it is important that HCPs and the pharmaceutical industry remain focused on their individual core activities, strengths and limitations. To me, the ethical challenge in any collaboration is how to work together despite having different overall aims, expectations and legal limitations. As an HCP, I can work with pharma on scientific issues, medical questions and a dialogue for better understanding. I cannot, however, be seen as a collaborator on joint educational projects as I see that as inappropriate because of the inherent COI of the pharma industry, and this is in my view a good example of where the arms-length principle is important.
I worry when I see the pharmaceutical industry expanding education of HCPs, supporting patient groups/organizations or working directly with public payors. In my view, the core activity of the pharmaceutical industry is the discovery and production of drugs. No one else does this and dilution of this activity will invariably lead to poorer future treatments. I fear that more and more companies will – even in the short term – expand their activities into other buyer/user/payor-focused activities, often areas where COIs are unavoidable. I would hope for a closer collaboration in new ways of discovering and delivering drugs for the benefit of the industry, HCPs – and patients.”
Jorgen Vestbo, President, European Respiratory Society, Switzerland
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Dr. Asma Ibrahim Al Mannaei, Director, Healthcare Quality Division | HAAD
Strategize your Risk Management Plan in 2 steps
Read below the interview with Judy to reveal the latest trends in risk management and find out what are the most important steps towards strategizing your risk management plan.
A prescription of Quality and Efficiency in the right doses
Read below the interview with Ronan to understand the importance of balance between quality and efficiency and reveal which pitfalls to avoid.